Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 26;14(9):636. doi: 10.1038/s41419-023-06053-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A The heatmap of four key transcriptional regulators and other immune markers in the primary cohort. Apart from SCLC molecular subtype, other clinical features were also annotated, including age, gender, smoking history, and TNM stage. B Differences in immune cell infiltration across the four SCLC subtypes. C, D, E Survival analysis by SCLC molecular subtypes in the primary and public cohorts. ASCL1 achaete-scute homologue 1, FOXP3 forkhead box protein P3, LAG3 lymphocyte activation gene-3, MHC-II major histocompatibility complex Class II, NEUROD1, neurogenic differentiation factor 1, ns not significant, OS overall survival; OX40L OX40 ligand, PFS progression-free survival, POU2F3 POU class 2 homeobox 3, PD-1 program death-1, PD-L1 program death-ligand 1, RFS recurrence-free survival, TCs tumor cells, TILs tumor infiltrating lymphocytes, TIM3 T cell immunoglobulin and mucin-domain containing-3, YAP1 yes-associated protein 1; *p < 0.05.